Literature DB >> 9374132

Cellular uptake of lipoprotein[a] by mouse embryonic fibroblasts via the LDL receptor and the LDL receptor-related protein.

T Reblin1, A Niemeier, N Meyer, T E Willnow, F Kronenberg, H Dieplinger, H Greten, U Beisiegel.   

Abstract

The sites and precise mechanisms of the catabolism of the atherogenic lipoprotein[a] (Lp[a]) are unknown. It has been proposed that the low density lipoprotein receptor (LDL-R) and the low density lipoprotein receptor-related protein (LRP) are involved in the catabolism of Lp[a]. To address the question whether and to what extent the LDL-R and/or LRP are involved in the catabolism of Lp[a], we studied the cellular uptake of Lp[a] via those two receptors using mouse embryonic fibroblast (MEF) cell lines lacking either the LDL-R, the LRP, or both receptors due to disruption of the respective mouse genes. 125I-labeled LDL and 125I-labeled Lp[a] uptake by wild-type fibroblasts (MEF1) was compared with that by fibroblasts homozygous for the disrupted LRP allele (MEF2), fibroblasts with two defective alleles for the LDL-R (MEF3), and fibroblasts homozygous for defects both in the LDL-R and LRP gene (MEF4). Compared with MEF1, 125I-labeled LDL uptake by MEF2 was 77%, by MEF3 30%, and by MEF4 24% of that by MEF1. However, no significant differences in the specific 125I-labeled Lp[a] uptake by the four mouse embryonic cell lines was observed. In comparison with MEF1, the 125I-labeled Lp[a] uptake by MEF2 was 98%, by MEF3 111%, and 73% by MEF4. Approximately 50% of the total cellular uptake of 125I-labeled Lp[a] was nonspecific. In conclusion, our results suggest that Lp[a] is a poor ligand for the LDL receptor and the LRP. The data of the displacement studies, however, indicated that the nonspecific uptake of Lp[a] constitutes a major route for the cellular Lp[a] catabolism in this study.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9374132

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  8 in total

1.  Galactose-specific asialoglycoprotein receptor is involved in lipoprotein (a) catabolism.

Authors:  Andelko Hrzenjak; Sasa Frank; Xingde Wo; Yonggang Zhou; Theo Van Berkel; Gert M Kostner
Journal:  Biochem J       Date:  2003-12-15       Impact factor: 3.857

2.  Receptor-associated protein interacts with amyloid-beta peptide and promotes its cellular uptake.

Authors:  Takahisa Kanekiyo; Guojun Bu
Journal:  J Biol Chem       Date:  2009-10-13       Impact factor: 5.157

Review 3.  Lipoprotein(a) metabolism: potential sites for therapeutic targets.

Authors:  Jane Hoover-Plow; Menggui Huang
Journal:  Metabolism       Date:  2012-10-04       Impact factor: 8.694

4.  Scavenger receptor-BI is a receptor for lipoprotein(a).

Authors:  Xiao-Ping Yang; Marcelo J Amar; Boris Vaisman; Alexander V Bocharov; Tatyana G Vishnyakova; Lita A Freeman; Roger J Kurlander; Amy P Patterson; Lewis C Becker; Alan T Remaley
Journal:  J Lipid Res       Date:  2013-06-29       Impact factor: 5.922

5.  Lipoprotein (a) upregulates ABCA1 in liver cells via scavenger receptor-B1 through its oxidized phospholipids.

Authors:  Monika Sharma; Anne Von Zychlinski-Kleffmann; Carolyn M Porteous; Gregory T Jones; Michael J A Williams; Sally P A McCormick
Journal:  J Lipid Res       Date:  2015-04-06       Impact factor: 5.922

6.  Proprotein convertase subtilisin/kexin type 9 levels and aortic valve calcification: A prospective, cross sectional study.

Authors:  Wen-Guang Wang; Yong-Feng He; Yuan-Li Chen; Fu-Mei Zhao; Yan-Qiu Song; Hong Zhang; Yan-He Ma; Xin Guan; Wen-Ya Zhang; Xiao-Lin Chen; Chao Liu; Hong-Liang Cong
Journal:  J Int Med Res       Date:  2016-06-08       Impact factor: 1.671

7.  Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.

Authors:  Rocco Romagnuolo; Corey A Scipione; Santica M Marcovina; Matthew Gemin; Nabil G Seidah; Michael B Boffa; Marlys L Koschinsky
Journal:  PLoS One       Date:  2017-07-27       Impact factor: 3.240

8.  PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab.

Authors:  Elise F Villard; Aurélie Thedrez; Jorg Blankenstein; Mikaël Croyal; Thi-Thu-Trang Tran; Bruno Poirier; Jean-Christophe Le Bail; Stéphane Illiano; Estelle Nobécourt; Michel Krempf; Dirk J Blom; A David Marais; Philip Janiak; Anthony J Muslin; Etienne Guillot; Gilles Lambert
Journal:  JACC Basic Transl Sci       Date:  2016-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.